What is Polaryx Therapeutics, Inc. 's accrued expenses?

Polaryx Therapeutics, Inc. (PLYX) reported accrued expenses of $21K in Q4 2025.

What does accrued expenses mean?

Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.

FTAI Aviation Ltd.FTAI

$96.77M+6.3%

Restaurant Brands InternationalQSR

$98M-6.7%

LittelfuseLFUS

$89.16M+55.5%

Guidewire SoftwareGWRE

$117.53M+31.7%

International PaperIP

$693M+16.3%

HalliburtonHAL

$622M-1.6%

Operating income-$2.0M+61.2%

Net income-$2.5M+49.6%

EPS (diluted)-$0.05+54.5%

Cash & equivalents$3.1M+1,132%

Total equity$2.5M-41.5%

Total assets$3.5M—

Operating cash flow-$2.1M-191%

Market cap$115.64M—

Return on equity-1,209.8%—

Current ratio3.5×—

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: Polaryx Therapeutics, Inc. ’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Polaryx Therapeutics, Inc. 's accrued expenses?: Polaryx Therapeutics, Inc. (PLYX) reported accrued expenses of $21K in Q4 2025.
What does accrued expenses mean?: Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.